A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

NCT06126783 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease, TED

Interventions

DRUG: IBI311

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.